Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Summary
Primary Objective: * To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended dose (RD) of SAR408701 in Japanese patients with advanced malignant solid tumors. Secondary Objectives: * To characterize the overall safety profile of SAR408701 monotherapy. * To characterize the pharmacokinetic (PK) profile of SAR408701 and its metabolites. * To evaluate the pharmacodynamic (PDy) effect of SAR408701 on levels of circulating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for main dose escalation part. * To assess preliminary efficacy according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria and other indicators of antitumor activity. * To assess the potential immunogenicity of SAR408701.
Timeline
- Start
- 2017-10-17
- Primary completion
- 2022-11-18
- Completion
- 2022-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tusamitamab ravtansine | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Tusamitamab ravtansine | Other / unclassified | 170 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | — | Other |
| Background | Diphenhydramine | Unknown | — | Oral |
| Background | Naphazoline | Small molecule | — | Other |